 After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the affected trials. After discussions with the FDA, Gilead has “discontinued safety follow-up” for the phase 2/3 Wonders-2 trial, “effectively terminating the study,” a company spokesperson confirmed to Fierce Biotech. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
